nach oben

Erschienen in:

21.06.2018 | Original Article

Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma

verfasst von: Huohui Ou, Yu Huang, Leyang Xiang, Zhanjun Chen, Yinghao Fang, Yixiong Lin, Zhonglin Cui, Sheng Yu, Xianghong Li, Dinghua Yang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Circulating tumors cells (CTCs) may be a promising prognostic marker for patients with malignant tumors. However, there are few reports regarding its value for hepatocellular carcinoma (HCC) patients.

Aims

To investigate CTCs with epithelial and mesenchymal phenotypes as a potential prognostic biomarker for HCC patients.

Methods

Peripheral blood samples were obtained from 165 HCC patients before radical surgery. CTCs were isolated via the CanPatrol CTC enrichment technique and classified using epithelial–mesenchymal transition (EMT) markers. The relationship of CTC phenotype with clinicopathological factors and HCC recurrence in patients was analyzed.

Results

CTC-positive status (count ≥ 2/5 mL) was found in 70.9% of the 165 HCC patients. Increased CTC number was more common in patients with higher AFP levels, multiple tumors, advanced TNM and BCLC staging, and presence of embolus or microembolus (P < 0.05). CTCs heterogeneity was noted using EMT markers. Mesenchymal CTCs were significantly correlated with high AFP levels, multiple tumors, advanced TNM and BCLC stage, presence of embolus or microembolus, and earlier recurrence (P < 0.05). The presence of mesenchymal CTCs predicted the shortest relapse-free survival, followed by mixed phenotypic CTCs, and then epithelial CTCs (P < 0.001).

Conclusion

CTC phenotype may serve as a prognostic indicator for HCC patients. CTCs assessment should include phenotypic identification tailored to characterize cells based on epithelial and mesenchymal markers.

Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. https://doi.org/10.3978/j.issn.1000-9604.2015.01.06.CrossRefPubMedPubMedCentral

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.CrossRefPubMed

Liu H, Zhang X, Li J, et al. The biological and clinical importance of epithelial–mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol. 2015;141:189.CrossRefPubMed

Liang B, Jia C, Huang Y, et al. TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci. 2015;60:2360–2372.CrossRefPubMed

Qin LX. Tang ZY Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130:497–513.CrossRefPubMed

Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023–2029. https://doi.org/10.1158/1078-0432.CCR-06-2701.CrossRefPubMed

Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791. https://doi.org/10.1056/NEJMoa040766.CrossRefPubMed

Chausovsky G, Luchansky M, Figer A, et al. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer Am Cancer Soc. 1999;86:2398–2405.

Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239. https://doi.org/10.1038/nature06385.CrossRefPubMedPubMedCentral

10.

Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17:827–835. https://doi.org/10.1158/1078-0432.CCR-10-0445.CrossRefPubMed

11.

Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166:21–45. https://doi.org/10.1016/j.cell.2016.06.028.CrossRefPubMed

12.

Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–829. https://doi.org/10.1016/j.devcel.2008.05.009.CrossRefPubMed

13.

Thiery JP, Acloque H, Huang RY, et al. Epithelial–mesenchymal transitions in development and disease. Cell. 2009;139:871–890. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

14.

Lee JM, Dedhar S, Kalluri R, et al. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–981. https://doi.org/10.1083/jcb.200601018.CrossRefPubMedPubMedCentral

15.

Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol. 2014;25:1506.CrossRefPubMed

16.

Kallergi G, Papadaki MA, Politaki E, et al. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011;13:R59. https://doi.org/10.1186/bcr2896.CrossRefPubMedPubMedCentral

17.

Min AL, Choi JY, Woo HY, et al. High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin Exp Metastas. 2009;26:759–767.CrossRef

18.

Li YM, Xu SC, Li J, et al. Epithelial–mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis. 2013;4:e831.CrossRefPubMedPubMedCentral

19.

Wu S, Liu S, Liu Z, et al. Classification of circulating tumor cells by epithelial–mesenchymal transition markers. PLoS ONE. 2015;10:e123976.

20.

Liu X, Ou H, Xiang L, et al. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget. 2017;8:10510.PubMedPubMedCentral

21.

Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepat Pancreat Surg. 2008;15:189–195. https://doi.org/10.1007/s00534-007-1250-5.CrossRef

22.

de Albuquerque A, Kubisch I, Breier G, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncol Basel. 2012;82:3–10. https://doi.org/10.1159/000335479.CrossRef

23.

Tjensvoll K, Nordgard O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer. 2014;134:1–8. https://doi.org/10.1002/ijc.28134.CrossRefPubMed

24.

Z’Graggen K, Centeno BA, Fernandez-del CC, et al. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery. 2001;129:537–546. https://doi.org/10.1067/msy.2001.113819.CrossRefPubMed

25.

Soeth E, Grigoleit U, Moellmann B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005;131:669–676. https://doi.org/10.1007/s00432-005-0008-1.CrossRefPubMed

26.

Okabe H, Tsunoda S, Hosogi H, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22:1–8.CrossRef

27.

Abrahamsson J, Aaltonen K, Engilbertsson H, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35:606.e9–606.e16.CrossRef

28.

Li Y, Cheng X, Chen Z, et al. Circulating tumor cells in peripheral and pulmonary venous blood predict poor long-term survival in resected non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys. 2014;90:S49.CrossRef

29.

Qiao Y, Li J, Shi C, et al. Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. Oncotargets Therapy. 2017;10:1363–1373.CrossRefPubMed

30.

Zhao R, Cai Z, Li S, et al. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget. 2016;8:9293.PubMedCentral

31.

Polioudaki H, Agelaki S, Chiotaki R, et al. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC Cancer. 2015;15:1–10.CrossRef

Titel: Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma
verfasst von: Huohui Ou
Yu Huang
Leyang Xiang
Zhanjun Chen
Yinghao Fang
Yixiong Lin
Zhonglin Cui
Sheng Yu
Xianghong Li
Dinghua Yang
Publikationsdatum: 21.06.2018
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5124-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

A Systematic Review of the Effectiveness of Psychological Treatments for IBS in Gastroenterology Settings: Promising but in Need of Further Study

Autologous Flap Transfer for Esophageal Stricture Prevention After Endoscopic Submucosal Dissection in a Porcine Model

Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms

Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration